Response and survival by treatment characteristics
| . | CR + CRu (%) . | P . | 5-y FFS rate, % . | P . | 5-y survival rate, % . | P . |
|---|---|---|---|---|---|---|
| Age | ||||||
| < 60 y | 90/102 (88) | .009 | 52 | .02 | 86 | .04 |
| ≥ 60 y | 28/40 (70) | 29 | 74 | |||
| No. extranodal sites | ||||||
| 0-1 | 80/91 (88) | .04 | 46 | .4 | 87 | .2 |
| > 1 | 38/51 (75) | 43 | 76 | |||
| LDH | ||||||
| ≤ 618 IU/L | 103/123 (84) | .6 | 46 | .3 | 86 | .08 |
| > 618 IU/L | 15/19 (79) | 42 | 68 | |||
| β2-Microglobulin | ||||||
| Low | 98/111 (88) | .002 | 53 | .0002 | 86 | .1 |
| High (≥ 3 mg/L) | 20/31 (65) | 14 | 74 | |||
| Histology | ||||||
| Follicular | 95/112 (85) | .3 | 46 | .5 | 82 | .5 |
| SL variants | 23/30 (77) | 43 | 86 | |||
| IPI | ||||||
| 1 | 82/94 (87) | .07 | 52 | .03 | 88 | .03 |
| ≥ 2 | 36/48 (75) | 32 | 74 | |||
| Treatment arm | ||||||
| FND | 58/73 (79) | .2 | 41 | .02 | 84 | .9 |
| ATT | 60/69 (87) | 50 | 82 | |||
| Bcl-2 rearrangement4-150 | ||||||
| Bcl-2 rearranged | 64/72 (89) | .06 | 51 | .04 | 88 | .04 |
| Germ line | 23/31 (74) | 34 | 71 | |||
| Molecular response4-151 | ||||||
| Molecular response | 47/50 (94) | .01 | 64 | .1 | 95 | .1 |
| No molecular response | 13/18 (72) | 28 | 76 |
| . | CR + CRu (%) . | P . | 5-y FFS rate, % . | P . | 5-y survival rate, % . | P . |
|---|---|---|---|---|---|---|
| Age | ||||||
| < 60 y | 90/102 (88) | .009 | 52 | .02 | 86 | .04 |
| ≥ 60 y | 28/40 (70) | 29 | 74 | |||
| No. extranodal sites | ||||||
| 0-1 | 80/91 (88) | .04 | 46 | .4 | 87 | .2 |
| > 1 | 38/51 (75) | 43 | 76 | |||
| LDH | ||||||
| ≤ 618 IU/L | 103/123 (84) | .6 | 46 | .3 | 86 | .08 |
| > 618 IU/L | 15/19 (79) | 42 | 68 | |||
| β2-Microglobulin | ||||||
| Low | 98/111 (88) | .002 | 53 | .0002 | 86 | .1 |
| High (≥ 3 mg/L) | 20/31 (65) | 14 | 74 | |||
| Histology | ||||||
| Follicular | 95/112 (85) | .3 | 46 | .5 | 82 | .5 |
| SL variants | 23/30 (77) | 43 | 86 | |||
| IPI | ||||||
| 1 | 82/94 (87) | .07 | 52 | .03 | 88 | .03 |
| ≥ 2 | 36/48 (75) | 32 | 74 | |||
| Treatment arm | ||||||
| FND | 58/73 (79) | .2 | 41 | .02 | 84 | .9 |
| ATT | 60/69 (87) | 50 | 82 | |||
| Bcl-2 rearrangement4-150 | ||||||
| Bcl-2 rearranged | 64/72 (89) | .06 | 51 | .04 | 88 | .04 |
| Germ line | 23/31 (74) | 34 | 71 | |||
| Molecular response4-151 | ||||||
| Molecular response | 47/50 (94) | .01 | 64 | .1 | 95 | .1 |
| No molecular response | 13/18 (72) | 28 | 76 |
Bulky disease was defined as any mass with a maximum diameter ≥ 5 cm.24 “Germ line” denotes patients for whom neither major breakpoint region (MBR) nor minor cluster region (mcr) rearrangements were detected with PCR in peripheral blood or bone marrow samples pretreatment.
Univariate analysis was used for data; for multivariate analysis of FFS, see text. LDH, lactate dehydrogenase.
For follicular lymphoma patients, excluding 9 for whom bcl-2 status was unknown.
For FFS and overall survival, 12-month landmark analysis was used (see “Patients and methods”).